If a patient misses three consecutive weekly injections of Wegovy (semaglutide) 2.4 mg, how should the medication be restarted?

Restarting Wegovy After Missing 3 Weeks

If a patient misses three consecutive weekly injections of Wegovy (semaglutide 2.4 mg), the medication should be restarted using the full titration schedule beginning at 0.25 mg weekly, rather than resuming at the previous dose. 1

Why Full Titration Is Required

When ≥3 consecutive doses are missed, the drug has been cleared from the body (semaglutide has a half-life of approximately 1 week), and gastrointestinal tolerance has been lost. 1, 2 Restarting at a higher dose without re-titration dramatically increases the risk of severe nausea, vomiting, and treatment discontinuation. 2, 3

Recommended Restart Protocol

Follow this stepwise titration schedule:

• Weeks 1–4: 0.25 mg subcutaneously once weekly 1, 2, 4
• Weeks 5–8: 0.5 mg once weekly 1, 2, 4
• Weeks 9–12: 1.0 mg once weekly 1, 2, 4
• Weeks 13–16: 1.7 mg once weekly 1, 2, 4
• Week 17 onward: 2.4 mg once weekly (maintenance dose) 1, 2, 4

The entire titration takes approximately 16–20 weeks to reach the maintenance dose of 2.4 mg. 1, 2

Critical Monitoring During Restart

• Assess gastrointestinal tolerance every 4 weeks before advancing to the next dose level; only escalate if the current dose is well tolerated. 1, 2
• Monitor for persistent severe abdominal pain (potential pancreatitis) and discontinue immediately if suspected. 1, 2, 4
• Check blood pressure every 4 weeks during titration, as weight loss may necessitate antihypertensive medication adjustments. 1
• Evaluate weight-loss efficacy at 12–16 weeks on the maximum tolerated dose; discontinue if <5% body weight loss after 3 months. 1, 2

What NOT to Do

• Do not restart at 2.4 mg or any intermediate dose (e.g., 1.0 mg or 1.7 mg) after missing ≥3 doses, as this bypasses the necessary gastrointestinal adaptation period and markedly increases adverse events. 1, 2
• Do not skip the 0.25 mg starting dose even though the patient previously tolerated higher doses; the 3-week gap has eliminated prior tolerance. 2

Expected Adverse Events During Titration

Gastrointestinal symptoms are common but typically mild-to-moderate and transient:

• Nausea: 18–44% of patients 1, 5, 3
• Diarrhea: ~12–32% 1, 5
• Vomiting: 8–25% 1, 5

These symptoms usually resolve within 4–8 weeks at each dose level with continued exposure. 1, 5

Contraindications to Restarting

Before reinitiating Wegovy, confirm the patient does not have:

• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2) – absolute contraindication 1, 2, 4
• Active pancreatitis or symptomatic gallbladder disease – relative contraindication 1, 2

Lifestyle Requirements

Wegovy must be combined with:

• Daily caloric deficit of ~500 kcal below maintenance requirements 1, 5
• ≥150 minutes per week of moderate-intensity physical activity 1, 5

Key Takeaway

Missing 3 weeks (≥3 consecutive doses) requires complete re-titration starting at 0.25 mg weekly to rebuild gastrointestinal tolerance and minimize adverse events. 1, 2 This approach balances safety with the goal of returning to the therapeutic 2.4 mg maintenance dose within 16–20 weeks. 1, 2